Allergo-immunopathology mechanism of thymol-inhibiting airway remodeling in asthmatic mice by regulating TGF-β/Smad3 pathway

• Liyuan Zhang ^[2] ; Wenna Zhang ^[2] ; Yanan Wang ^[2] ; Pei Cai ^[2] ; Chaoran Li ^[2] ; Yan Shi ^[2] ; Seyyed Shamsadin Athari ^[1] ; Ailing Li ^[2]
  1. [1] Zanjan University of Medical Sciences

     Zanjan University of Medical Sciences

     Irán

     
  2. [2] Department of Respiratory and Critical Care Medicine, Xi’an International Medical Center Hospital, Xi’an, 710100, China
• Localización: Allergologia et immunopathologia: International journal for clinical and investigate allergology and clinical immunology, ISSN-e 1578-1267, ISSN 0301-0546, Vol. 52, Nº. 5, 2024, págs. 51-58
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Allergic asthma is an important public health problem and is a complicated respiratory sickness that is characterized by bronchial inflammation, bronchoconstriction, and breathlessness. Asthma is orchestrated by type 2 immune response and remodeling is one of the important outputted problem in chronic asthma. Thymol is a naturally occurring monocyclic phenolic, it has a series of biological properties, and its immunomodulatory and anti-remodeling effects on allergic asthma were evaluated. The OVA-LPS-induced asthmatic mice were treated with thymol. Methacholine challenge test, eosinophil count, and levels of IL-4, IL-5, IL-13, and IL-33 in bronchoalveolar lavage fluid, total and OVA-specific IgE levels in serum, remodeling factors, gene expression of TGF-β, Smad2, Smad3, and lung histopathology were done. Treatment with thymol could control AHR, eosinophil percentage levels of Th2 cytokines and Igs, remodeling factors, expression of TGF-β, Smad2 and Smad3 genes, inflammation, goblet cell hyperplasia, and mucus production in asthmatic mice. Thymol can control asthma pathogens and related remodeling and fibrosis bio-factors and can be a potential treatment of asthma.